Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials
L Scisciola, V Cataldo, F Taktaz… - Frontiers in …, 2022 - frontiersin.org
Atherosclerosis is a progressive inflammatory disease leading to mortality and morbidity in
the civilized world. Atherosclerosis manifests as an accumulation of plaques in the intimal …
the civilized world. Atherosclerosis manifests as an accumulation of plaques in the intimal …
Coronary microvascular dysfunction in diabetes mellitus: pathogenetic mechanisms and potential therapeutic options
T Salvatore, R Galiero, A Caturano, E Vetrano… - Biomedicines, 2022 - mdpi.com
Diabetic patients are frequently affected by coronary microvascular dysfunction (CMD), a
condition consisting of a combination of altered vasomotion and long-term structural change …
condition consisting of a combination of altered vasomotion and long-term structural change …
SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients
P Mone, F Varzideh, SS Jankauskas, A Pansini… - …, 2022 - Am Heart Assoc
Background: Frailty is a multidimensional condition often diagnosed in older adults with
hypertension and diabetes, and both these conditions are associated with endothelial …
hypertension and diabetes, and both these conditions are associated with endothelial …
Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011-2018
W Guo, Y Song, Y Sun, H Du, Y Cai, Q You… - Frontiers in …, 2022 - frontiersin.org
Objective Diabetic kidney disease (DKD) is the most common chronic kidney disease (CKD)
and has the highest prevalence of end-stage kidney disease (ESKD) globally, owing mostly …
and has the highest prevalence of end-stage kidney disease (ESKD) globally, owing mostly …
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
N Shakour, S Karami, M Iranshahi, AE Butler… - Diabetes & Metabolic …, 2023 - Elsevier
Background and aims Scar tissue accumulation in organs is the underlying cause of many
fibrotic diseases. Due to the extensive array of organs affected, the long-term nature of …
fibrotic diseases. Due to the extensive array of organs affected, the long-term nature of …
Current and future strategies for targeting the endothelin pathway in cardiovascular disease
GR Abraham, TL Williams, JJ Maguire… - Nature Cardiovascular …, 2023 - nature.com
Abstract The first endothelin (ET)-1 receptor antagonist was approved for clinical use over
20 years ago, but to date this class of compounds has been limited to treating pulmonary …
20 years ago, but to date this class of compounds has been limited to treating pulmonary …
SGLT2 inhibitors in the treatment of diabetic kidney disease: more than just glucose regulation
J Klen, V Dolžan - Pharmaceutics, 2023 - mdpi.com
Diabetic kidney disease (DKD) is a severe and common complication and affects a quarter
of patients with type 2 diabetes mellitus (T2DM). Oxidative stress and inflammation related to …
of patients with type 2 diabetes mellitus (T2DM). Oxidative stress and inflammation related to …
New insight in cardiorenal syndrome: from biomarkers to therapy
Cardiorenal syndrome consists in the coexistence of acute or chronic dysfunction of heart
and kidneys resulting in a cascade of feedback mechanisms and causing damage to both …
and kidneys resulting in a cascade of feedback mechanisms and causing damage to both …
Effects of a combination of empagliflozin plus metformin vs. metformin monotherapy on NAFLD progression in type 2 diabetes: the IMAGIN pilot study
A Caturano, R Galiero, G Loffredo, E Vetrano… - Biomedicines, 2023 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) comprises a heterogeneous group of metabolic
liver diseases and is characterized by the presence of steatosis in at least 5% of …
liver diseases and is characterized by the presence of steatosis in at least 5% of …
Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms
A Belančić, S Klobučar - Diabetology, 2023 - mdpi.com
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been linked to beneficial effects
on cardiovascular risk factors, blood pressure, body weight, and lipid profile, according to a …
on cardiovascular risk factors, blood pressure, body weight, and lipid profile, according to a …